In invasive breast cancer, TIL infiltration has been reported to be predominant in hormone receptor (HR)-negative tumors including HER2+ and triple-negative subtypes as opposed to HR-positive tumors [14, 25]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.